文献速递前列腺癌

积极监测治疗GG1前列腺癌的长期结局及MRI对过度治疗的影响

Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
PubMed 文献 · BJU Int · 2025-04-14

PRIAS研究纳入全球169个中心的8910例GG1前列腺癌患者,评估积极监测的长期结局。15年根治性治疗累积发生率为55%,转移为2.7%,前列腺癌特异性死亡为0.23%。在监测前18个月内进行MRI与更高的≥GG2重分类风险相关,导致治疗率增加但短期复发风险无显著差异。

要点

  • GG1前列腺癌积极监测15年转移率2.7%,特异性死亡率0.23%。
  • 监测早期MRI增加GG2检出和治疗率,但5年复发风险无显著增加。
  • 为减少过度治疗,应扩大积极监测的入选标准并推广至 favourable GG2患者。

核心结论

  • GG1前列腺癌积极监测安全,15年转移和特异性死亡率低。
  • MRI纳入监测增加GG2检出和治疗率,但短期复发风险相似,需扩大监测适用性以减少过度治疗。

研究设计与样本

  • PRIAS研究为多中心、前瞻性、基于网络的队列研究。
  • 共纳入8910例GG1前列腺癌患者,来自全球169个中心。
  • 采用竞争风险分析估计累积发生率,多变量分析评估重分类风险。

主要发现

  • 诊断后15年根治性治疗累积发生率为55%(95%CI 53-57)。
  • 15年转移累积发生率为2.7%(95%CI 1.5-4.4)。
  • 8例死于前列腺癌,15年前列腺癌特异性死亡累积发生率为0.23%(95%CI 0.09-0.54)。
  • 与诊断时未行MRI者相比,监测前18个月内行MRI与更高的≥GG2重分类风险显著相关。
  • 诊断前MRI阳性与GG2重分类风险升高相关,但与≥GG3无关;MRI靶向再活检为GG2并接受根治性治疗者,5年疾病复发风险与监测中末次活检为GG1者相比无统计学显著差异。

临床怎么用

  • GG1前列腺癌患者可安全接受积极监测,长期转移和死亡风险低。
  • MRI可提高GG2检出,但需注意由此增加的治疗率,避免过度治疗。
  • 考虑扩大积极监测入选标准,并将 favourable GG2患者纳入监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To present the long-term outcomes of men with Grade Group (GG) 1 prostate cancer (PCa), included in the Prostate Cancer Research International Active Surveillance (PRIAS) study, and to assess the effect of the inclusion of magnetic resonance imaging (MRI) within the active surveillance (AS) protocol. PATIENTS AND METHODS: The PRIAS study is a multicentre, prospective, web-based cohort study monitoring patients on AS. In total, 8910 men with GG1 PCa were followed in 169 centres worldwide. The cumulative incidences of definitive treatment, metastasis and PCa-specific mortality (PCSM) were estimated using competing risk analyses. Additionally, multivariable analysis was performed to assess the risk of reclassification, stratified by MRI performed around the time of diagnosis. RESULTS: The cumulative incidence of definitive treatment 15 years post-diagnosis was 55% (95% confidence interval [CI] 53-57). For metastasis, the 15-year cumulative incidence was 2.7% (95% CI 1.5-4.4). Eight men of died from PCa, resulting in a 15-year cumulative PCSM incidence of 0.23% (95% CI 0.09-0.54). Compared to men with no MRI around the time of diagnosis, those who underwent MRI during the first 18 months of AS were associated with a significantly higher risk of reclassification to ≥GG2, while men with a positive MRI before diagnosis were associated with a higher risk of reclassification to GG2, but not to ≥GG3. Men with GG2 PCa on MRI-targeted rebiopsy who underwent definitive treatment did not show a statistically significant higher risk of 5-year disease recurrence compared to those who had GG1 PCa on last biopsy during AS. CONCLUSIONS: Our study confirms the safety of AS for GG1 PCa, with low metastasis and PCSM rates over 15 years. Furthermore, the inclusion of MRI in AS prompts increased detection of GG2, leading to increased treatment rates despite similar short-term risks. To minimise overtreatment, expanding eligibility for AS and the uptake of AS in men with favourable GG2 PCa is crucial to address the stage shift resulting from the increased accuracy of MRI.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. de Vos II, Marenghi C, Badenchini F, et al. Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int. 2025. PMID: 40223578. doi:10.1111/bju.16727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。